Differentiating Benign from Malignant Thyroid Tumors by Kinase Activity Profiling and Dabrafenib BRAF V600E Targeting.
通过激酶活性分析和达拉非尼BRAF V600E靶向治疗区分良性甲状腺肿瘤和恶性甲状腺肿瘤
期刊:Cancers
影响因子:4.4
doi:10.3390/cancers15184477
Hilhorst Riet, van den Berg Adrienne, Boender Piet, van Wezel Tom, Kievits Tim, de Wijn Rik, Ruijtenbeek Rob, Corver Willem E, Morreau Hans
